Contrast injector technology firm Medrad of Warrendale, PA, plans to highlight its personalized-protocol software that individualizes CT pulmonary angiography (CTPA) contrast dosing at the upcoming RSNA meeting.
The company's P3T PA (pulmonary angiography) software allows for improved diagnostic-quality studies by fitting into a facility's established CTPA workflow and making consistent administration of personalized contrast dosing practical, according to Medrad.
The software's algorithm tailors each patient's contrast protocol based on technologists' touchscreen responses to particular clinical concerns, study requirements, and the scanning equipment used, Medrad said.
Related Reading
Medrad signs Novation deal, August 23, 2010
Medrad signs distribution pact, August 3, 2010
Medrad gets FDA OK for Intego, July 7, 2010
Medrad inks PET deal with MGH, June 7, 2010
Medrad, Pinestar team up, May 19, 2010
Copyright © 2010 AuntMinnie.com
![Axial images from unenhanced calcium score cardiac CT (left) and curved planar reformation images from CT angiography (right) show that higher long-term exposure to air pollution is associated with greater coronary artery calcium and more obstructive coronary artery disease (CAD). Top row: Images in a 68-year-old male patient with higher 10-year mean ambient air pollution exposure (7.9 μg/m3 for particulate matter measuring ≤2.5 μm in diameter [PM2.5] and 17.4 parts per billion [ppb] for NO2) with extensive CAD (coronary artery calcium score [CACS] >1,000 and obstructive CAD [≥70% diameter stenosis]). Bottom row: Images in a 57-year-old female patient with lower 10-year mean ambient air pollution exposure (6.3 μg/m3 for PM2.5 and 4.6 ppb for NO2) with no CAD (CACS = 0 and no obstructive stenosis).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/06/hanneman.r6SMLzkezo.png?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
